These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20851657)

  • 1. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
    Kubandova Z; Mathieu S; Pourtier C; Soubrier M
    Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.
    Wendling D; Streit G; Toussirot E; Prati C
    Joint Bone Spine; 2008 Oct; 75(5):540-3. PubMed ID: 18674945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
    Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
    Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
    [No Abstract]   [Full Text] [Related]  

  • 5. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
    Kondo H
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of varicella during adalimumab therapy.
    Lee DH; Kim HS; Song YW; Cho KH
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):687-8. PubMed ID: 17447988
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?
    Bongartz T; Orenstein R
    Nat Rev Rheumatol; 2009 Jul; 5(7):361-3. PubMed ID: 19568250
    [No Abstract]   [Full Text] [Related]  

  • 10. Herpes zoster in the age of focused immunosuppressive therapy.
    Whitley RJ; Gnann JW
    JAMA; 2009 Feb; 301(7):774-5. PubMed ID: 19224757
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-6: a new therapeutic target.
    Smolen JS; Maini RN
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
    Choy E
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii68-9. PubMed ID: 14532153
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
    Patel AM; Moreland LW
    Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases.
    Nagamine R; Chen W; Hara T; Kondo K; Sugioka Y
    Mod Rheumatol; 2009; 19(3):348-50. PubMed ID: 19288171
    [No Abstract]   [Full Text] [Related]  

  • 15. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 inhibition--tolerability profile and clinical implications.
    Strand V; Yazici Y
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
    Ogata A; Morishima A; Hirano T; Hishitani Y; Hagihara K; Shima Y; Narazaki M; Tanaka T
    Ann Rheum Dis; 2011 Jun; 70(6):1164-5. PubMed ID: 20980285
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 19. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.